CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Prucalopride for Gastrointestinal Motility Disorders: A Review of Clinical Effectiveness

Last updated: December 6, 2017
Project Number: RC0944-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report


  1. What is the clinical effectiveness of prucalopride for the treatment of gastrointestinal motility disorders (i.e., chronic constipation, ileus, refractory gastroparesis, intestinal pseudo-obstruction)?

Key Message

Findings from three SRs showed that prucalopride seems to be a beneficial pharmacotherapy in the treatment of chronic constipation, but with an increase in adverse event rates compared to placebo. Indirect comparison showed there was no significant difference in efficacy among prucalopride and other pharmacotherapies. Limited evidence from two RCTs found prucalopride is a safe and effective treatment to reduce the symptoms of post-operative ileus and chronic intestinal pseudo-obstruction. There was no evidence found on the comparative efficacy of prucalopride for refractory gastroparesis.